Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
06
01
2021
accepted:
25
01
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Highly HLA-sensitized kidney transplant candidates are difficult to desensitize, which reduces their chances of receiving a transplant. We administered tocilizumab as a monotherapy (8 mg/kg once a mo) to 14 highly sensitized kidney transplant candidates. Highest mean fluorescence intensities of anti-HLA antibodies obtained before and after tocilizumab administration were compared from raw and diluted sera. The administration of tocilizumab significantly reduced dominant anti-HLA antibody sensitization. However, this decrease in mean fluorescence intensities was minor compared with the initial values. Tocilizumab as a monotherapy was not sufficient to allow highly sensitized kidney-transplant candidates to undergo transplantation and, therefore, was not an effective desensitization method.
Sections du résumé
BACKGROUND
BACKGROUND
Highly HLA-sensitized kidney transplant candidates are difficult to desensitize, which reduces their chances of receiving a transplant.
METHODS
METHODS
We administered tocilizumab as a monotherapy (8 mg/kg once a mo) to 14 highly sensitized kidney transplant candidates. Highest mean fluorescence intensities of anti-HLA antibodies obtained before and after tocilizumab administration were compared from raw and diluted sera.
RESULTS
RESULTS
The administration of tocilizumab significantly reduced dominant anti-HLA antibody sensitization. However, this decrease in mean fluorescence intensities was minor compared with the initial values.
CONCLUSIONS
CONCLUSIONS
Tocilizumab as a monotherapy was not sufficient to allow highly sensitized kidney-transplant candidates to undergo transplantation and, therefore, was not an effective desensitization method.
Identifiants
pubmed: 33912657
doi: 10.1097/TXD.0000000000001139
pmc: PMC8078280
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e690Informations de copyright
Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Exp Clin Transplant. 2019 Aug;17(4):483-489
pubmed: 30346267
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1773-80
pubmed: 25237071
Arthritis Rheum. 2010 Feb;62(2):542-52
pubmed: 20112381
N Engl J Med. 2017 Aug 3;377(5):442-453
pubmed: 28767349
Transpl Immunol. 2013 Mar;28(2-3):138-43
pubmed: 23562586
Exp Clin Transplant. 2015 Apr;13 Suppl 1:165-9
pubmed: 25894148
Clin Transplant. 2016 May;30(5):545-55
pubmed: 26914805
Clin Transplant. 2020 Aug;34(8):e13908
pubmed: 32415711
Transplantation. 2013 Apr 15;95(7):943-8
pubmed: 23425817
Front Immunol. 2016 Nov 23;7:520
pubmed: 27933060
Int Immunopharmacol. 2020 Aug;85:106649
pubmed: 32504999
Arthritis Rheum. 2011 May;63(5):1255-64
pubmed: 21305508
Arthritis Res Ther. 2015 Jan 21;17:10
pubmed: 25604867
PLoS One. 2016 Jan 05;11(1):e0146075
pubmed: 26730981
Exp Clin Transplant. 2018 Aug;16(4):367-375
pubmed: 29863455
Transpl Int. 2016 Dec;29(12):1276-1285
pubmed: 27529314
Atheroscler Suppl. 2013 Jan;14(1):199-202
pubmed: 23357165
Transplantation. 2020 Apr;104(4):856-863
pubmed: 31385933
Transplantation. 2015 Nov;99(11):2356-63
pubmed: 26018350
J Immunol. 2015 Mar 15;194(6):2482-5
pubmed: 25681343
Nephrol Dial Transplant. 2019 Apr 1;34(4):555-560
pubmed: 29897595
N Engl J Med. 2011 Jul 28;365(4):318-26
pubmed: 21793744
Arthritis Res Ther. 2015 Mar 14;17:61
pubmed: 25888920
Drugs. 2017 Nov;77(17):1865-1879
pubmed: 29094311